HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $180
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on BioNTech (NASDAQ:BNTX) but lowers the price target from $181 to $180.
August 10, 2023 | 11:42 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BioNTech's price target has been lowered by HC Wainwright & Co. from $181 to $180, though the 'Buy' rating is maintained.
The lowering of the price target by $1 suggests a slight decrease in expected future performance. However, the maintenance of the 'Buy' rating indicates that the analyst still believes in the company's potential. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100